rituximab ITP
Selected indexed studies
- Rituximab resistance in ITP and beyond. (Front Immunol, 2023) [PMID:37575230]
- Recent advances in the management of immune thrombocytopenic purpura (ITP): A comprehensive review. (Medicine (Baltimore), 2024) [PMID:38241567]
- Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. (Ann Hematol, 2022) [PMID:35201417]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Recent advances in the management of immune thrombocytopenic purpura (ITP): A comprehensive review. (2024) pubmed
- Current Understanding of Immune Thrombocytopenia: A Review of Pathogenesis and Treatment Options. (2024) pubmed
- Rituximab resistance in ITP and beyond. (2023) pubmed
- Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy. (2024) pubmed
- Immune thrombocytopenia. (2021) pubmed
- Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. (2020) pubmed
- Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives. (2022) pubmed
- Evans' Syndrome: From Diagnosis to Treatment. (2020) pubmed
- Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP). (2017) pubmed
- All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. (2022) pubmed